Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2021-11-17 00:00:00 ET · period of report 2021-11-16 · accession 0000886163-21-000136 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-17 | 2021-11-16 | LGND | LAMATTINA JOHN L | Dir | M - OptEx | $32.30 | +4,835 | 30.2K | +19% | +$156.2K |
| D | 2021-11-17 | 2021-11-16 | LGND | LAMATTINA JOHN L | Dir | S - Sale+OE | $161.86 | -4,835 | 25.4K | -16% | -$782.6K |
| D | 2021-11-17 | 2021-11-16 | LGND | LAMATTINA JOHN L | Dir | M - OptEx | $0.00 | -4,835 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-16 | M | A | 4,835 | $32.30 | 30,233 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-16 | S | D | 4,835 | $161.86 | 25,398 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.36 to $164.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-11-16 | M | D | 4,835 | $0.00 | 0 | D | $32.30 · — to 2023-06-11 | 4,835 Common Stock | (F2) Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date. |